mylan inc - health news
Mylan Inc. announced yesterday that it plans to launch a generic version of Copaxone, Teva Pharmaceutical Industries Ltd. intravenous treatment for multiple sclerosis, in the second half of 2013. Mylan added that patent litigation and US Food and Drug Administration (FDA) approval of its drug are pending. In addition, the firm announced yesterday that it has entered into a facility agreement with a syndicate of banks to securitize up to $300 million of U.S. accounts receivable. The facility is committed and has a maturity of three years. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

AI Startup Helps Doctors Analyze Heart Scans
February 08, 2023

AI Monitors High-Speed Conveyor Belts For Defects
February 08, 2023

Israel Hi-Tech Group In Rescue Mission To Turkey
February 08, 2023

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023
Facebook comments